Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linarazen Gluconate + Amoxicillin vs Bismuth Quadruple Therapy for First-Line H. pylori Eradication
NCT07897994Phase 4Recruiting
- Sponsor
- Yongquan Shi
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Helicobacter pylori infection (2 arms), sponsored by Yongquan Shi. Primary endpoint: Helicobacter pylori eradication rate. Started Oct 2026; status: recruiting.
02
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07897994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897994.